Artwork

Content provided by HBR Presents / Brian Kenny. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HBR Presents / Brian Kenny or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?

21:17
 
Share
 

Manage episode 231250586 series 2500985
Content provided by HBR Presents / Brian Kenny. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HBR Presents / Brian Kenny or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. Brian Alexander at the Dana-Farber Cancer Center in Boston was in the process of launching a new type of clinical trial: an adaptive platform trial. Unlike the traditional randomized controlled trial, adaptive platform trials facilitate simultaneously studying multiple therapies for a given disease and have the potential to make clinical trials for new cancer drugs more efficient and accessible to patients. Developing questions around design, operations, and financing set the stage for this discussion with Harvard Business School professor Ariel Stern about her case: “Adaptive Platform Trials: The Clinical Trial of the Future?”

  continue reading

232 episodes

Artwork
iconShare
 
Manage episode 231250586 series 2500985
Content provided by HBR Presents / Brian Kenny. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HBR Presents / Brian Kenny or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. Brian Alexander at the Dana-Farber Cancer Center in Boston was in the process of launching a new type of clinical trial: an adaptive platform trial. Unlike the traditional randomized controlled trial, adaptive platform trials facilitate simultaneously studying multiple therapies for a given disease and have the potential to make clinical trials for new cancer drugs more efficient and accessible to patients. Developing questions around design, operations, and financing set the stage for this discussion with Harvard Business School professor Ariel Stern about her case: “Adaptive Platform Trials: The Clinical Trial of the Future?”

  continue reading

232 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide